Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
China Life
BioCentury | Jan 2, 2025
Editor's Commentary
Biosecure litmus test: Editor’s Commentary
Lesson one from the Biosecure Act: U.S. biotech policy must focus on bolstering the domestic bioeconomy
BioCentury | Mar 22, 2024
Politics, Policy & Law
Congress broadening anti-China life sciences focus
Senators investigating biotech, calling for export restrictions
BioCentury | Feb 27, 2024
Finance
Insights from Bob Nelsen and developments in TL1A inhibitors, rare diseases: BioCentury’s latest podcast
Plus: The latest on anti-China policies in Congress
BioCentury | Sep 7, 2023
Finance
China biotech moving to first, best in class
High-speed clinical research pathway for cell therapies creates competitive advantage, Panacea’s Huang says
BioCentury | Jul 31, 2023
Finance
China Venture Quick Takes: Pyrotech raises $97M series A
Plus: Series B round for immunology company Xinkanghe, and updates from Migrasome, Immuno Cure and Forward
BioCentury | Jul 26, 2023
Data Byte
Sharp increase in therapeutics deals from China to the West
Western companies struck 7x more deals to access Chinese tech last year than in 2013, and 2023 could see another increase
BioCentury | Feb 14, 2023
Guest Commentary
A rational approach to tapping China’s growing digital health trend
What companies need to consider in deciding whether and how to bring digital health products to China: a guest commentary
BioCentury | Dec 10, 2022
Product Development
Dec. 9 Quick Takes: Trio of biotechs parlays data into follow-ons
Plus: Erasca adds pan-RAF inhibitor from Novartis, and updates from UCB, Ambrx, Pharvaris and more
BioCentury | Nov 15, 2022
Product Development
Annual BayHelix awards highlight China’s maturing life sciences sector
Legend, Insilico, Turning Point, Immune-Onc among winners; Joan Shen named Woman Leader of Year
BioCentury | Oct 4, 2022
Product Development
Wins in neurodegeneration, U.S.-China & Life Science Cares: a BioCentury podcast
Big wins in Alzheimer’s, ALS, with bigger implications
Items per page:
1 - 10 of 41